iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: https://pubmed.ncbi.nlm.nih.gov/2185906
Clinical pharmacokinetics of imipramine and desipramine - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 1990 May;18(5):346-64.
doi: 10.2165/00003088-199018050-00002.

Clinical pharmacokinetics of imipramine and desipramine

F R Sallee  1 , B G Pollock
Affiliations
Review

Clinical pharmacokinetics of imipramine and desipramine

F R Sallee et al. Clin Pharmacokinet. 1990 May.

Abstract

The pharmacokinetics of imipramine and desipramine have been extensively investigated with recent studies designed to understand sources of intersubject variability and to study discrete clinical populations rather than healthy volunteers. Sources of intersubject variability in pharmacokinetics are both genetic (oxidative phenotype) and environmental. Oxidative phenotype has an important impact on first-pass metabolism. In individuals with poor metabolism, systemic availability for imipramine is increased. Intrinsic clearance of desipramine is reduced 4-fold in individuals with poor metabolism. Recent pharmacokinetic studies in diverse patient populations such as the depressed elderly, children and alcoholics have revealed decreased clearance of imipramine in the elderly and increased clearance of both imipramine and desipramine in chronic alcoholics. In at least a third of the population, nonlinear pharmacokinetics of desipramine may be observed at steady-state plasma concentrations above 150 micrograms/L. These nonlinear changes in desipramine pharmacokinetics are not associated with age or sex, but are associated with higher desipramine 2-hydroxydesipramine concentration ratios. Hydroxylated metabolites of imipramine and desipramine may possess both antidepressants and cardiotoxic activity but their formation is rate limited and plasma concentrations tend to follow the parent compound with little accumulation. The potent cardiovascular effects of the hydroxymetabolites may be particularly relevant for the elderly and in acute overdose.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ther Drug Monit. 1985;7(2):239-41 - PubMed
    1. Psychopharmacology (Berl). 1986;88(4):505-13 - PubMed
    1. Eur J Clin Pharmacol. 1979 Sep;16(3):183-7 - PubMed
    1. Clin Pharmacol Ther. 1985 Oct;38(4):394-401 - PubMed
    1. Ann N Y Acad Sci. 1962 Jan 13;96:279-88 - PubMed

Publication types

LinkOut - more resources